IMMUNOTHERAPY Benefit with anti-PD-L1

被引：1
|
作者：
Romero, Diana
机构：
来源：
NATURE REVIEWS CLINICAL ONCOLOGY | 2017年 / 14卷 / 02期
关键词：
D O I：
10.1038/nrclinonc.2016.218
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：70 / 70
页数：1
相关论文
共 50 条
  • [1] Benefit with anti-PD-L1
    Diana Romero
    Nature Reviews Clinical Oncology, 2017, 14 : 71 - 71
  • [2] Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy
    Li, Xiao
    Eastham, Jeffrey
    Giltnane, Jennifer M.
    Zou, Wei
    Zijlstra, Andries
    Tabatsky, Evgeniy
    Banchereau, Romain
    Chang, Ching-Wei
    Nabet, Barzin Y.
    Patil, Namrata S.
    Molinero, Luciana
    Chui, Steve
    Harryman, Maureen
    Lau, Shari
    Rangell, Linda
    Waumans, Yannick
    Kockx, Mark
    Orlova, Darya
    Koeppen, Hartmut
    JOURNAL OF PATHOLOGY, 2024, 263 (02): : 190 - 202
  • [3] Hair Repigmentation With Anti-PD-1 and Anti-PD-L1 Immunotherapy: A Novel Hypothesis
    Manson, Guillaume
    Marabelle, Aurelien
    Houot, Roch
    JAMA DERMATOLOGY, 2018, 154 (01) : 113 - 113
  • [4] Discovery of small anti-PD-L1 peptides for cancer immunotherapy
    Liu, Hao
    Zhao, Zhen
    Li, Yuanke
    Cheng, Kun
    CANCER RESEARCH, 2019, 79 (13)
  • [5] A Novel Anti-PD-L1 Vaccine for Cancer Immunotherapy and Immunoprevention
    Chen, Jie
    Liu, Hui
    Jehng, Tiffany
    Li, Yanqing
    Chen, Zhoushi
    Lee, Kuan-Der
    Shen, Hsieh-Tsung
    Jones, Lindsey
    Huang, Xue F.
    Chen, Si-Yi
    CANCERS, 2019, 11 (12)
  • [6] ANTI-PD-1 AND ANTI-PD-L1 ANTIBODIES AS IMMUNOTHERAPY AGAINST CANCER: A STRUCTURAL PERSPECTIVE
    Cordova-Bahena, Luis
    Velasco-Velazquez, Marco A.
    REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2021, 73 (01): : 8 - 16
  • [7] In anti-PD-L1 immunotherapy FcγR interaction can add additional benefit depending on the tumor model
    Verbeek, J. S.
    Sow, H. S.
    Benonisson, H.
    Breukel, C.
    Visser, R.
    Verhagen, O.
    Bentlage, A.
    Brouwers, C.
    Claassens, J.
    Linssen, M.
    Camps, M.
    van Hall, T.
    Ossendorp, F.
    Herbert-Fransen, M.
    Vidarsson, G.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1733 - 1734
  • [8] MYASTHENIA GRAVIS CRISIS COMPLICATING ANTI-PD-L1 CANCER IMMUNOTHERAPY
    Chae, June
    Peikert, Tobias
    CRITICAL CARE MEDICINE, 2018, 46 (01) : 280 - 280
  • [9] Intestinal microbiota may dynamically facilitate the anti-PD-L1 immunotherapy
    Xue, Jia
    Wang, Zhun
    Guo, Sheng
    Cai, Jie
    Ouyang, Davy
    Cai, Bin
    Chen, Gang
    Liu, Jie
    Dong, Xin
    Li, Henry
    CANCER RESEARCH, 2017, 77
  • [10] Discovery of Anti-PD-L1 Human Domain Antibodies for Cancer Immunotherapy
    Liu, Hao
    Liu, Yanli
    Zhao, Zhen
    Li, Yuanke
    Mustafa, Bahaa
    Chen, Zhijin
    Barve, Ashutosh
    Jain, Akshay
    Yao, Xiaolan
    Li, Guangfu
    Cheng, Kun
    FRONTIERS IN IMMUNOLOGY, 2022, 13
12345